{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T06:28:11Z","timestamp":1786343291775,"version":"build-2736575974"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03743-9","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:33:35Z","timestamp":1786340015000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival Motor Neuron Protein Requirement\u2013Supply Mismatch in Spinal Muscular Atrophy: A Conceptual Framework"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-4222","authenticated-orcid":false,"given":"Kentaro","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"3743_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155\u201365. https:\/\/doi.org\/10.1016\/0092-8674(95)90460-3.","journal-title":"Cell"},{"key":"3743_CR2","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","volume":"8","author":"UR Monani","year":"1999","unstructured":"Monani UR, Lorson CL, Parsons DW, et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet. 1999;8:1177\u201383. https:\/\/doi.org\/10.1093\/hmg\/8.7.1177.","journal-title":"Hum Mol Genet"},{"key":"3743_CR3","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","volume":"96","author":"CL Lorson","year":"1999","unstructured":"Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A. 1999;96:6307\u201311. https:\/\/doi.org\/10.1073\/pnas.96.11.6307.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3743_CR4","doi-asserted-by":"publisher","first-page":"9920","DOI":"10.1073\/pnas.94.18.9920","volume":"94","author":"B Schrank","year":"1997","unstructured":"Schrank B, G\u00f6tz R, Gunnersen JM, et al. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci U S A. 1997;94:9920\u20135. https:\/\/doi.org\/10.1073\/pnas.94.18.9920.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3743_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/hmg\/9.3.333","volume":"9","author":"UR Monani","year":"2000","unstructured":"Monani UR, Sendtner M, Coovert DD, et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-\/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet. 2000;9:333\u20139. https:\/\/doi.org\/10.1093\/hmg\/9.3.333.","journal-title":"Hum Mol Genet"},{"key":"3743_CR6","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1086\/338627","volume":"70","author":"M Feldk\u00f6tter","year":"2002","unstructured":"Feldk\u00f6tter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002;70:358\u201368. https:\/\/doi.org\/10.1086\/338627.","journal-title":"Am J Hum Genet"},{"key":"3743_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho M, Bernal S, Al\u00edas L, et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018;28:208\u201315. https:\/\/doi.org\/10.1016\/j.nmd.2018.01.003.","journal-title":"Neuromuscul Disord"},{"key":"3743_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.24497","volume":"51","author":"WD Arnold","year":"2015","unstructured":"Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve. 2015;51:157\u201367. https:\/\/doi.org\/10.1002\/mus.24497.","journal-title":"Muscle Nerve"},{"key":"3743_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D\u2019Amico","year":"2011","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71. https:\/\/doi.org\/10.1186\/1750-1172-6-71.","journal-title":"Orphanet J Rare Dis"},{"key":"3743_CR10","unstructured":"Prior TW, Leach ME, Finanger EL. Spinal muscular atrophy. 2000 Feb 24 [Updated 2026 Feb 12]. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993\u20132026. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1352\/. Accessed 6 Apr 2026."},{"key":"3743_CR11","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1172\/JCI124120","volume":"129","author":"DM Ramos","year":"2019","unstructured":"Ramos DM, d\u2019Ydewalle C, Gabbeta V, et al. Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment. J Clin Invest. 2019;129:4817\u201331. https:\/\/doi.org\/10.1172\/JCI124120.","journal-title":"J Clin Invest"},{"key":"3743_CR12","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/gt.2017.46","volume":"24","author":"S Jablonka","year":"2017","unstructured":"Jablonka S, Sendtner M. Developmental regulation of SMN expression: pathophysiological implications and perspectives for therapy development in spinal muscular atrophy. Gene Ther. 2017;24:506\u201313. https:\/\/doi.org\/10.1038\/gt.2017.46.","journal-title":"Gene Ther"},{"key":"3743_CR13","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1093\/hmg\/ddy195","volume":"27","author":"EJN Groen","year":"2018","unstructured":"Groen EJN, Perenthaler E, Courtney NL, et al. Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy. Hum Mol Genet. 2018;27:2851\u201362. https:\/\/doi.org\/10.1093\/hmg\/ddy195.","journal-title":"Hum Mol Genet"},{"key":"3743_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/ng0797-265","volume":"16","author":"S Lefebvre","year":"1997","unstructured":"Lefebvre S, Burlet P, Liu Q, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. 1997;16:265\u20139. https:\/\/doi.org\/10.1038\/ng0797-265.","journal-title":"Nat Genet"},{"key":"3743_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/ajmg.a.30251","volume":"130A","author":"TW Prior","year":"2004","unstructured":"Prior TW, Swoboda KJ, Scott HD, Hejmanowski AQ. Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. Am J Med Genet A. 2004;130A:307\u201310. https:\/\/doi.org\/10.1002\/ajmg.a.30251.","journal-title":"Am J Med Genet A"},{"key":"3743_CR16","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/ejhg.2008.41","volume":"16","author":"M Jedrzejowska","year":"2008","unstructured":"Jedrzejowska M, Borkowska J, Zimowski J, et al. Unaffected patients with a homozygous absence of the SMN1 gene. Eur J Hum Genet. 2008;16:930\u20134. https:\/\/doi.org\/10.1038\/ejhg.2008.41.","journal-title":"Eur J Hum Genet"},{"key":"3743_CR17","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1702752.","journal-title":"N Engl J Med"},{"key":"3743_CR18","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1706198.","journal-title":"N Engl J Med"},{"key":"3743_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1710504.","journal-title":"N Engl J Med"},{"key":"3743_CR20","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW, et al. Risdiplam in type\u00a01 spinal muscular atrophy. N Engl J Med. 2021;384:915\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2009965.","journal-title":"N Engl J Med"},{"key":"3743_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Deconinck N, Mazzone ES, et al. Safety and efficacy of once-daily risdiplam in type\u00a02 and non-ambulant type\u00a03 spinal muscular atrophy (SUNFISH part 2): a phase\u00a03, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022;21:42\u201352. https:\/\/doi.org\/10.1016\/S1474-4422(21)00367-7.","journal-title":"Lancet Neurol"},{"key":"3743_CR22","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase\u00a02 NURTURE study. Neuromuscul Disord. 2019;29:842\u201356. https:\/\/doi.org\/10.1016\/j.nmd.2019.09.007.","journal-title":"Neuromuscul Disord"},{"key":"3743_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27853","volume":"68","author":"TO Crawford","year":"2023","unstructured":"Crawford TO, Swoboda KJ, De Vivo DC, et al. Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study. Muscle Nerve. 2023;68:157\u201370. https:\/\/doi.org\/10.1002\/mus.27853.","journal-title":"Muscle Nerve"},{"key":"3743_CR24","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type\u00a01: the phase\u00a0III SPR1NT trial. Nat Med. 2022;28:1381\u20139. https:\/\/doi.org\/10.1038\/s41591-022-01866-4.","journal-title":"Nat Med"},{"key":"3743_CR25","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the phase\u00a0III SPR1NT trial. Nat Med. 2022;28:1390\u20137. https:\/\/doi.org\/10.1038\/s41591-022-01867-3.","journal-title":"Nat Med"},{"key":"3743_CR26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1056\/NEJMoa2410120","volume":"393","author":"RS Finkel","year":"2025","unstructured":"Finkel RS, Servais L, Vlodavets D, et al. Risdiplam in presymptomatic spinal muscular atrophy. N Engl J Med. 2025;393:671\u201382. https:\/\/doi.org\/10.1056\/NEJMoa2410120.","journal-title":"N Engl J Med"},{"key":"3743_CR27","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/brain\/awac252","volume":"146","author":"A Pechmann","year":"2023","unstructured":"Pechmann A, Behrens M, D\u00f6rnbrack K, et al. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy. Brain. 2023;146:668\u201377. https:\/\/doi.org\/10.1093\/brain\/awac252.","journal-title":"Brain"},{"key":"3743_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jpeds.2019.12.047","volume":"219","author":"VA Sansone","year":"2020","unstructured":"Sansone VA, Pirola A, Albamonte E, et al. Respiratory needs in patients with type\u00a01 spinal muscular atrophy treated with nusinersen. J Pediatr. 2020;219:223-228.e4. https:\/\/doi.org\/10.1016\/j.jpeds.2019.12.047.","journal-title":"J Pediatr"},{"key":"3743_CR29","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1093\/hmg\/7.12.1927","volume":"7","author":"P Burlet","year":"1998","unstructured":"Burlet P, Huber C, Bertrandy S, et al. The distribution of SMN protein complex in human fetal tissues and its alteration in spinal muscular atrophy. Hum Mol Genet. 1998;7:1927\u201333. https:\/\/doi.org\/10.1093\/hmg\/7.12.1927.","journal-title":"Hum Mol Genet"},{"key":"3743_CR30","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1093\/hmg\/ddn189","volume":"17","author":"VL McGovern","year":"2008","unstructured":"McGovern VL, Gavrilina TO, Beattie CE, Burghes AHM. Embryonic motor axon development in the severe SMA mouse. Hum Mol Genet. 2008;17:2900\u20139. https:\/\/doi.org\/10.1093\/hmg\/ddn189.","journal-title":"Hum Mol Genet"},{"key":"3743_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb6871","volume":"13","author":"L Kong","year":"2021","unstructured":"Kong L, Valdivia DO, Simon CM, et al. Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA. Sci Transl Med. 2021;13:eabb6871. https:\/\/doi.org\/10.1126\/scitranslmed.abb6871.","journal-title":"Sci Transl Med"},{"key":"3743_CR32","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1083\/jcb.200304128","volume":"163","author":"W Rossoll","year":"2003","unstructured":"Rossoll W, Jablonka S, Andreassi C, et al. Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. J Cell Biol. 2003;163:801\u201312. https:\/\/doi.org\/10.1083\/jcb.200304128.","journal-title":"J Cell Biol"},{"key":"3743_CR33","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1093\/hmg\/ddn156","volume":"17","author":"S Kariya","year":"2008","unstructured":"Kariya S, Park G-H, Maeno-Hikichi Y, et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum Mol Genet. 2008;17:2552\u201369. https:\/\/doi.org\/10.1093\/hmg\/ddn156.","journal-title":"Hum Mol Genet"},{"key":"3743_CR34","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1523\/JNEUROSCI.4434-08.2009","volume":"29","author":"L Kong","year":"2009","unstructured":"Kong L, Wang X, Choe DW, et al. Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J Neurosci. 2009;29:842\u201351. https:\/\/doi.org\/10.1523\/JNEUROSCI.4434-08.2009.","journal-title":"J Neurosci"},{"key":"3743_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015457","volume":"5","author":"KKY Ling","year":"2010","unstructured":"Ling KKY, Lin M-Y, Zingg B, Feng Z, Ko C-P. Synaptic defects in the spinal and neuromuscular circuitry in a mouse model of spinal muscular atrophy. PLoS ONE. 2010;5:e15457. https:\/\/doi.org\/10.1371\/journal.pone.0015457.","journal-title":"PLoS ONE"},{"key":"3743_CR36","doi-asserted-by":"publisher","first-page":"8703","DOI":"10.1523\/JNEUROSCI.0204-12.2012","volume":"32","author":"TL Martinez","year":"2012","unstructured":"Martinez TL, Kong L, Wang X, et al. Survival motor neuron protein in motor neurons determines synaptic integrity in spinal muscular atrophy. J Neurosci. 2012;32:8703\u201315. https:\/\/doi.org\/10.1523\/JNEUROSCI.0204-12.2012.","journal-title":"J Neurosci"},{"key":"3743_CR37","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1093\/hmg\/ddr275","volume":"20","author":"TT Le","year":"2011","unstructured":"Le TT, McGovern VL, Alwine IE, et al. Temporal requirement for high SMN expression in SMA mice. Hum Mol Genet. 2011;20:3578\u201391. https:\/\/doi.org\/10.1093\/hmg\/ddr275.","journal-title":"Hum Mol Genet"},{"key":"3743_CR38","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1172\/JCI57291","volume":"121","author":"CM Lutz","year":"2011","unstructured":"Lutz CM, Kariya S, Patruni S, et al. Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. J Clin Invest. 2011;121:3029\u201341. https:\/\/doi.org\/10.1172\/JCI57291.","journal-title":"J Clin Invest"},{"key":"3743_CR39","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1093\/hmg\/ddu169","volume":"23","author":"KL Robbins","year":"2014","unstructured":"Robbins KL, Glascock JJ, Osman EY, Miller MR, Lorson CL. Defining the therapeutic window in a severe animal model of spinal muscular atrophy. Hum Mol Genet. 2014;23:4559\u201368. https:\/\/doi.org\/10.1093\/hmg\/ddu169.","journal-title":"Hum Mol Genet"},{"key":"3743_CR40","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1172\/JCI72017","volume":"124","author":"S Kariya","year":"2014","unstructured":"Kariya S, Obis T, Garone C, et al. Requirement of enhanced survival motoneuron protein imposed during neuromuscular junction maturation. J Clin Invest. 2014;124:785\u2013800. https:\/\/doi.org\/10.1172\/JCI72017.","journal-title":"J Clin Invest"},{"key":"3743_CR41","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1093\/hmg\/ddab220","volume":"31","author":"X Zhao","year":"2021","unstructured":"Zhao X, Feng Z, Risher N, et al. SMN protein is required throughout life to prevent spinal muscular atrophy disease progression. Hum Mol Genet. 2021;31:82\u201396. https:\/\/doi.org\/10.1093\/hmg\/ddab220.","journal-title":"Hum Mol Genet"},{"key":"3743_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.nbd.2012.08.019","volume":"49","author":"LM Murray","year":"2013","unstructured":"Murray LM, Beauvais A, Bhanot K, Kothary R. Defects in neuromuscular junction remodelling in the Smn(2B\/-) mouse model of spinal muscular atrophy. Neurobiol Dis. 2013;49:57\u201367. https:\/\/doi.org\/10.1016\/j.nbd.2012.08.019.","journal-title":"Neurobiol Dis"},{"key":"3743_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002030","volume":"7","author":"SJ Grice","year":"2011","unstructured":"Grice SJ, Liu J-L. Survival motor neuron protein regulates stem cell division, proliferation, and differentiation in Drosophila. PLoS Genet. 2011;7:e1002030. https:\/\/doi.org\/10.1371\/journal.pgen.1002030.","journal-title":"PLoS Genet"},{"key":"3743_CR44","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1093\/hmg\/ddaa146","volume":"29","author":"AAL Motyl","year":"2020","unstructured":"Motyl AAL, Faller KME, Groen EJN, et al. Pre-natal manifestation of systemic developmental abnormalities in spinal muscular atrophy. Hum Mol Genet. 2020;29:2674\u201383. https:\/\/doi.org\/10.1093\/hmg\/ddaa146.","journal-title":"Hum Mol Genet"},{"key":"3743_CR45","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1093\/hmg\/ddq340","volume":"19","author":"TM Wishart","year":"2010","unstructured":"Wishart TM, Huang JP-W, Murray LM, et al. SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. Hum Mol Genet. 2010;19:4216\u201328. https:\/\/doi.org\/10.1093\/hmg\/ddq340.","journal-title":"Hum Mol Genet"},{"key":"3743_CR46","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.192835","volume":"10","author":"F Genovese","year":"2025","unstructured":"Genovese F, Huang Y-T, Motyl AA, et al. Prenatal SMN-dependent defects in translation uncover reversible primary cilia phenotypes in spinal muscular atrophy. JCI Insight. 2025;10:e192835. https:\/\/doi.org\/10.1172\/jci.insight.192835.","journal-title":"JCI Insight"},{"key":"3743_CR47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/NEN.0000000000000144","volume":"74","author":"BN Harding","year":"2015","unstructured":"Harding BN, Kariya S, Monani UR, et al. Spectrum of neuropathophysiology in spinal muscular atrophy type\u00a0I. J Neuropathol Exp Neurol. 2015;74:15\u201324. https:\/\/doi.org\/10.1097\/NEN.0000000000000144.","journal-title":"J Neuropathol Exp Neurol"},{"key":"3743_CR48","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/ana.25549","volume":"86","author":"RH Mendon\u00e7a","year":"2019","unstructured":"Mendon\u00e7a RH, Rocha AJ, Lozano-Arango A, et al. Severe brain involvement in 5q spinal muscular atrophy type\u00a00. Ann Neurol. 2019;86:458\u201362. https:\/\/doi.org\/10.1002\/ana.25549.","journal-title":"Ann Neurol"},{"key":"3743_CR49","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","volume":"24","author":"Y Hua","year":"2010","unstructured":"Hua Y, Sahashi K, Hung G, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type\u00a0III SMA mouse model. Genes Dev. 2010;24:1634\u201344. https:\/\/doi.org\/10.1101\/gad.1941310.","journal-title":"Genes Dev"},{"key":"3743_CR50","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/hmg\/ddr600","volume":"21","author":"PN Porensky","year":"2012","unstructured":"Porensky PN, Mitrpant C, McGovern VL, et al. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet. 2012;21:1625\u201338. https:\/\/doi.org\/10.1093\/hmg\/ddr600.","journal-title":"Hum Mol Genet"},{"key":"3743_CR51","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ygeno.2015.01.007","volume":"105","author":"JF Staropoli","year":"2015","unstructured":"Staropoli JF, Li H, Chun SJ, et al. Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon\u00a07. Genomics. 2015;105:220\u20138. https:\/\/doi.org\/10.1016\/j.ygeno.2015.01.007.","journal-title":"Genomics"},{"key":"3743_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3233\/JND-230136","volume":"11","author":"H K\u00f6lbel","year":"2024","unstructured":"K\u00f6lbel H, Kopka M, Modler L, et al. Impaired neurodevelopment in children with 5q-SMA - 2\u00a0years after newborn screening. J Neuromuscul Dis. 2024;11:143\u201351. https:\/\/doi.org\/10.3233\/JND-230136.","journal-title":"J Neuromuscul Dis"},{"key":"3743_CR53","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/emmm.201302567","volume":"5","author":"K Sahashi","year":"2013","unstructured":"Sahashi K, Ling KKY, Hua Y, et al. Pathological impact of SMN2 mis-splicing in adult SMA mice. EMBO Mol Med. 2013;5:1586\u2013601. https:\/\/doi.org\/10.1002\/emmm.201302567.","journal-title":"EMBO Mol Med"},{"key":"3743_CR54","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/NEN.0b013e3181a10ea1","volume":"68","author":"R Mart\u00ednez-Hern\u00e1ndez","year":"2009","unstructured":"Mart\u00ednez-Hern\u00e1ndez R, Soler-Botija C, Also E, et al. The developmental pattern of myotubes in spinal muscular atrophy indicates prenatal delay of muscle maturation. J Neuropathol Exp Neurol. 2009;68:474\u201381. https:\/\/doi.org\/10.1097\/NEN.0b013e3181a10ea1.","journal-title":"J Neuropathol Exp Neurol"},{"key":"3743_CR55","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1083\/jcb.152.5.1107","volume":"152","author":"C Cifuentes-Diaz","year":"2001","unstructured":"Cifuentes-Diaz C, Frugier T, Tiziano FD, et al. Deletion of murine SMN exon\u00a07 directed to skeletal muscle leads to severe muscular dystrophy. J Cell Biol. 2001;152:1107\u201314. https:\/\/doi.org\/10.1083\/jcb.152.5.1107.","journal-title":"J Cell Biol"},{"key":"3743_CR56","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.21873\/invivo.12161","volume":"34","author":"S Ando","year":"2020","unstructured":"Ando S, Tanaka M, Chinen N, Nakamura S, Shimazawa M, Hara H. SMN protein contributes to skeletal muscle cell maturation via caspase-3 and Akt activation. In Vivo. 2020;34:3247\u201354. https:\/\/doi.org\/10.21873\/invivo.12161.","journal-title":"In Vivo"},{"key":"3743_CR57","doi-asserted-by":"publisher","first-page":"89","DOI":"10.36185\/2532-1900-558","volume":"43","author":"C Hedberg-Oldfors","year":"2024","unstructured":"Hedberg-Oldfors C, Jennions E, Visuttijai K, Oldfors A. Abnormal expression of myosin heavy chains in early postnatal stages of spinal muscular atrophy type\u00a0I at single fibre level. Acta Myol. 2024;43:89\u201394. https:\/\/doi.org\/10.36185\/2532-1900-558.","journal-title":"Acta Myol"},{"key":"3743_CR58","doi-asserted-by":"publisher","first-page":"e202201457","DOI":"10.26508\/lsa.202201457","volume":"6","author":"A Ikenaka","year":"2023","unstructured":"Ikenaka A, Kitagawa Y, Yoshida M, et al. SMN promotes mitochondrial metabolic maturation during myogenesis by regulating the MYOD-miRNA axis. Life Sci Alliance. 2023;6:e202201457. https:\/\/doi.org\/10.26508\/lsa.202201457.","journal-title":"Life Sci Alliance"},{"key":"3743_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212415","volume":"25","author":"MT Berciano","year":"2024","unstructured":"Berciano MT, Gatius A, Puente-Bedia A, et al. SMN deficiency induces an early non-atrophic myopathy with alterations in the contractile and excitatory coupling machinery of skeletal myofibers in the SMN\u22067 mouse model of spinal muscular atrophy. Int J Mol Sci. 2024;25:12415. https:\/\/doi.org\/10.3390\/ijms252212415.","journal-title":"Int J Mol Sci"},{"key":"3743_CR60","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/hmg\/ddae162","volume":"34","author":"H Liu","year":"2025","unstructured":"Liu H, Chehade L, Deguise M-O, De Repentigny Y, Kothary R. SMN depletion impairs skeletal muscle formation and maturation in a mouse model of SMA. Hum Mol Genet. 2025;34:21\u201331. https:\/\/doi.org\/10.1093\/hmg\/ddae162.","journal-title":"Hum Mol Genet"},{"key":"3743_CR61","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ydbio.2012.05.037","volume":"368","author":"M Hayhurst","year":"2012","unstructured":"Hayhurst M, Wagner AK, Cerletti M, Wagers AJ, Rubin LL. A cell-autonomous defect in skeletal muscle satellite cells expressing low levels of survival of motor neuron protein. Dev Biol. 2012;368:323\u201334. https:\/\/doi.org\/10.1016\/j.ydbio.2012.05.037.","journal-title":"Dev Biol"},{"key":"3743_CR62","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/hmg\/ddm379","volume":"17","author":"TO Gavrilina","year":"2008","unstructured":"Gavrilina TO, McGovern VL, Workman E, et al. Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect. Hum Mol Genet. 2008;17:1063\u201375. https:\/\/doi.org\/10.1093\/hmg\/ddm379.","journal-title":"Hum Mol Genet"},{"key":"3743_CR63","doi-asserted-by":"publisher","first-page":"6160","DOI":"10.1093\/hmg\/ddv332","volume":"24","author":"CC Iyer","year":"2015","unstructured":"Iyer CC, McGovern VL, Murray JD, et al. Low levels of survival motor neuron protein are sufficient for normal muscle function in the SMN\u03947 mouse model of SMA. Hum Mol Genet. 2015;24:6160\u201373. https:\/\/doi.org\/10.1093\/hmg\/ddv332.","journal-title":"Hum Mol Genet"},{"key":"3743_CR64","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI131989","volume":"130","author":"J-K Kim","year":"2020","unstructured":"Kim J-K, Jha NN, Feng Z, et al. Muscle-specific SMN reduction reveals motor neuron-independent disease in spinal muscular atrophy models. J Clin Invest. 2020;130:1271\u201387. https:\/\/doi.org\/10.1172\/JCI131989.","journal-title":"J Clin Invest"},{"key":"3743_CR65","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awag045","author":"J Mecca","year":"2026","unstructured":"Mecca J, Mignot J, Gervais M, et al. Targeted knockdown of Smn in muscle stem cells induces non-cell autonomous loss of motor neurons. Brain. 2026. https:\/\/doi.org\/10.1093\/brain\/awag045.","journal-title":"Brain"},{"key":"3743_CR66","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.158380","volume":"7","author":"J-H Kim","year":"2022","unstructured":"Kim J-H, Kang J-S, Yoo K, et al. Bap1\/SMN axis in Dpp4+ skeletal muscle mesenchymal cells regulates the neuromuscular system. JCI Insight. 2022;7:e158380. https:\/\/doi.org\/10.1172\/jci.insight.158380.","journal-title":"JCI Insight"},{"key":"3743_CR67","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0002-9440(10)63428-1","volume":"165","author":"JM Vitte","year":"2004","unstructured":"Vitte JM, Davoult B, Roblot N, et al. Deletion of murine Smn exon\u00a07 directed to liver leads to severe defect of liver development associated with iron overload. Am J Pathol. 2004;165:1731\u201341. https:\/\/doi.org\/10.1016\/S0002-9440(10)63428-1.","journal-title":"Am J Pathol"},{"key":"3743_CR68","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.99141","volume":"13","author":"MMA de Almeida","year":"2025","unstructured":"de Almeida MMA, De Repentigny Y, Gagnon S, Sutton ER, Kothary R. Impact of liver-specific survival motor neuron (SMN) depletion on central nervous system and peripheral tissue pathology. Elife. 2025;13:RP99141. https:\/\/doi.org\/10.7554\/eLife.99141.","journal-title":"Elife"},{"key":"3743_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/srep34635","volume":"6","author":"E Szunyogova","year":"2016","unstructured":"Szunyogova E, Zhou H, Maxwell GK, et al. Survival motor neuron (SMN) protein is required for normal mouse liver development. Sci Rep. 2016;6:34635. https:\/\/doi.org\/10.1038\/srep34635.","journal-title":"Sci Rep"},{"key":"3743_CR70","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature10485","volume":"478","author":"Y Hua","year":"2011","unstructured":"Hua Y, Sahashi K, Rigo F, et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature. 2011;478:123\u20136. https:\/\/doi.org\/10.1038\/nature10485.","journal-title":"Nature"},{"key":"3743_CR71","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jcmgh.2021.01.019","volume":"12","author":"M-O Deguise","year":"2021","unstructured":"Deguise M-O, Pileggi C, De Repentigny Y, et al. SMN depleted mice offer a robust and rapid onset model of nonalcoholic fatty liver disease. Cell Mol Gastroenterol Hepatol. 2021;12:354-377.e3. https:\/\/doi.org\/10.1016\/j.jcmgh.2021.01.019.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"3743_CR72","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/ana.23582","volume":"72","author":"M Bowerman","year":"2012","unstructured":"Bowerman M, Swoboda KJ, Michalski J-P, et al. Glucose metabolism and pancreatic defects in spinal muscular atrophy. Ann Neurol. 2012;72:256\u201368. https:\/\/doi.org\/10.1002\/ana.23582.","journal-title":"Ann Neurol"},{"key":"3743_CR73","doi-asserted-by":"publisher","first-page":"e173702","DOI":"10.1172\/JCI173702","volume":"134","author":"DM-K Leow","year":"2024","unstructured":"Leow DM-K, Ng YK, Wang LC, et al. Hepatocyte-intrinsic SMN deficiency drives metabolic dysfunction and liver steatosis in spinal muscular atrophy. J Clin Invest. 2024;134:e173702. https:\/\/doi.org\/10.1172\/JCI173702.","journal-title":"J Clin Invest"},{"key":"3743_CR74","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/mus.28275","volume":"70","author":"M Rakusa","year":"2024","unstructured":"Rakusa M, Koritnik B, Leonardis L, et al. The endocrine manifestations of adults with spinal muscular atrophy. Muscle Nerve. 2024;70:1230\u20139. https:\/\/doi.org\/10.1002\/mus.28275.","journal-title":"Muscle Nerve"},{"key":"3743_CR75","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/acn3.50855","volume":"6","author":"M-O Deguise","year":"2019","unstructured":"Deguise M-O, Baranello G, Mastella C, et al. Abnormal fatty acid metabolism is a core component of spinal muscular atrophy. Ann Clin Transl Neurol. 2019;6:1519\u201332. https:\/\/doi.org\/10.1002\/acn3.50855.","journal-title":"Ann Clin Transl Neurol"},{"key":"3743_CR76","doi-asserted-by":"publisher","first-page":"105444","DOI":"10.1016\/j.ebiom.2024.105444","volume":"110","author":"ER Sutton","year":"2024","unstructured":"Sutton ER, Beauvais A, Yaworski R, et al. Liver SMN restoration rescues the Smn2B\/- mouse model of spinal muscular atrophy. EBioMedicine. 2024;110:105444. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105444.","journal-title":"EBioMedicine"},{"key":"3743_CR77","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jpeds.2015.09.023","volume":"167","author":"RH Davis","year":"2015","unstructured":"Davis RH, Miller EA, Zhang RZ, Swoboda KJ. Responses to fasting and glucose loading in a cohort of well children with spinal muscular atrophy type\u00a0II. J Pediatr. 2015;167:1362-1368.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2015.09.023.","journal-title":"J Pediatr"},{"key":"3743_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173144","volume":"12","author":"H K\u00f6lbel","year":"2017","unstructured":"K\u00f6lbel H, Hauffa BP, Wudy SA, Bouikidis A, Della Marina A, Schara U. Hyperleptinemia in children with autosomal recessive spinal muscular atrophy type\u00a0I-III. PLoS ONE. 2017;12:e0173144. https:\/\/doi.org\/10.1371\/journal.pone.0173144.","journal-title":"PLoS ONE"},{"key":"3743_CR79","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1093\/hmg\/ddaa145","volume":"29","author":"N Hensel","year":"2020","unstructured":"Hensel N, Brickwedde H, Tsaknakis K, et al. Altered bone development with impaired cartilage formation precedes neuromuscular symptoms in spinal muscular atrophy. Hum Mol Genet. 2020;29:2662\u201373. https:\/\/doi.org\/10.1093\/hmg\/ddaa145.","journal-title":"Hum Mol Genet"},{"key":"3743_CR80","doi-asserted-by":"publisher","first-page":"RP92731","DOI":"10.7554\/eLife.92731","volume":"12","author":"S-H Hann","year":"2024","unstructured":"Hann S-H, Kim S-Y, Kim YL, et al. Depletion of SMN protein in mesenchymal progenitors impairs the development of bone and neuromuscular junction in spinal muscular atrophy. Elife. 2024;12:RP92731. https:\/\/doi.org\/10.7554\/eLife.92731.","journal-title":"Elife"},{"key":"3743_CR81","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fped.2017.00194","volume":"5","author":"S Iwatani","year":"2017","unstructured":"Iwatani S, Harahap NIF, Nurputra DK, et al. Gestational age-dependent increase of survival motor neuron protein in umbilical cord-derived mesenchymal stem cells. Front Pediatr. 2017;5:194. https:\/\/doi.org\/10.3389\/fped.2017.00194.","journal-title":"Front Pediatr"},{"key":"3743_CR82","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/path.2566","volume":"219","author":"S Shanmugarajan","year":"2009","unstructured":"Shanmugarajan S, Tsuruga E, Swoboda KJ, Maria BL, Ries WL, Reddy SV. Bone loss in survival motor neuron (Smn(-\/-) SMN2) genetic mouse model of spinal muscular atrophy. J Pathol. 2009;219:52\u201360. https:\/\/doi.org\/10.1002\/path.2566.","journal-title":"J Pathol"},{"key":"3743_CR83","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.bone.2015.05.039","volume":"79","author":"S Vai","year":"2015","unstructured":"Vai S, Bianchi ML, Moroni I, et al. Bone and spinal muscular atrophy. Bone. 2015;79:116\u201320. https:\/\/doi.org\/10.1016\/j.bone.2015.05.039.","journal-title":"Bone"},{"key":"3743_CR84","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202501626R","volume":"39","author":"T Xiang","year":"2025","unstructured":"Xiang T, Zhou Z, Li Y, et al. Loss of SMN impairs osteoblast-osteoclast coupling via IGF1-Akt-OPG axis in spinal muscular atrophy. FASEB J. 2025;39:e71095. https:\/\/doi.org\/10.1096\/fj.202501626R.","journal-title":"FASEB J"},{"key":"3743_CR85","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41413-025-00473-6","volume":"13","author":"Z Zhou","year":"2025","unstructured":"Zhou Z, Fan X, Xiang T, et al. SMN deficiency inhibits endochondral ossification via promoting TRAF6-induced ubiquitination degradation of YBX1 in spinal muscular atrophy. Bone Res. 2025;13:97. https:\/\/doi.org\/10.1038\/s41413-025-00473-6.","journal-title":"Bone Res"},{"key":"3743_CR86","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1006\/bmme.1997.2590","volume":"61","author":"G Novelli","year":"1997","unstructured":"Novelli G, Calz\u00e0 L, Amicucci P, et al. Expression study of survival motor neuron gene in human fetal tissues. Biochem Mol Med. 1997;61:102\u20136. https:\/\/doi.org\/10.1006\/bmme.1997.2590.","journal-title":"Biochem Mol Med"},{"key":"3743_CR87","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/jmg.2008.057950","volume":"45","author":"S Rudnik-Sch\u00f6neborn","year":"2008","unstructured":"Rudnik-Sch\u00f6neborn S, Heller R, Berg C, et al. Congenital heart disease is a feature of severe infantile spinal muscular atrophy. J Med Genet. 2008;45:635\u20138. https:\/\/doi.org\/10.1136\/jmg.2008.057950.","journal-title":"J Med Genet"},{"key":"3743_CR88","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1093\/hmg\/ddq330","volume":"19","author":"CR Heier","year":"2010","unstructured":"Heier CR, Satta R, Lutz C, DiDonato CJ. Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Hum Mol Genet. 2010;19:3906\u201318. https:\/\/doi.org\/10.1093\/hmg\/ddq330.","journal-title":"Hum Mol Genet"},{"key":"3743_CR89","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/joa.12793","volume":"232","author":"GK Maxwell","year":"2018","unstructured":"Maxwell GK, Szunyogova E, Shorrock HK, Gillingwater TH, Parson SH. Developmental and degenerative cardiac defects in the Taiwanese mouse model of severe spinal muscular atrophy. J Anat. 2018;232:965\u201378. https:\/\/doi.org\/10.1111\/joa.12793.","journal-title":"J Anat"},{"key":"3743_CR90","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1093\/hmg\/ddq300","volume":"19","author":"AK Bevan","year":"2010","unstructured":"Bevan AK, Hutchinson KR, Foust KD, et al. Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum Mol Genet. 2010;19:3895\u2013905. https:\/\/doi.org\/10.1093\/hmg\/ddq300.","journal-title":"Hum Mol Genet"},{"key":"3743_CR91","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13395-020-00232-7","volume":"10","author":"G Khayrullina","year":"2020","unstructured":"Khayrullina G, Moritz KE, Schooley JF, et al. SMN-deficiency disrupts SERCA2 expression and intracellular Ca2+ signaling in cardiomyocytes from SMA mice and patient-derived iPSCs. Skelet Muscle. 2020;10:16. https:\/\/doi.org\/10.1186\/s13395-020-00232-7.","journal-title":"Skelet Muscle"},{"key":"3743_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2026.124361","volume":"394","author":"L Jiang","year":"2026","unstructured":"Jiang L, Wang X, Cui Y, et al. SMN deficiency-induced alternative splicing dysregulation in cardiac defects. Life Sci. 2026;394:124361. https:\/\/doi.org\/10.1016\/j.lfs.2026.124361.","journal-title":"Life Sci"},{"key":"3743_CR93","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1093\/hmg\/ddad121","volume":"32","author":"SJ Brown","year":"2023","unstructured":"Brown SJ, \u0160olti\u0107 D, Synowsky SA, et al. AAV9-mediated SMN gene therapy rescues cardiac desmin but not lamin A\/C and elastin dysregulation in Smn2B\/- spinal muscular atrophy mice. Hum Mol Genet. 2023;32:2950\u201365. https:\/\/doi.org\/10.1093\/hmg\/ddad121.","journal-title":"Hum Mol Genet"},{"key":"3743_CR94","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/hmg\/ddaf006","volume":"34","author":"NN Nair","year":"2025","unstructured":"Nair NN, Kline RA, Boyd I, et al. Alterations in cardiac function correlate with a disruption in fatty acid metabolism in a mouse model of SMA. Hum Mol Genet. 2025;34:547\u201362. https:\/\/doi.org\/10.1093\/hmg\/ddaf006.","journal-title":"Hum Mol Genet"},{"key":"3743_CR95","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1093\/hmg\/ddn234","volume":"17","author":"MP Walker","year":"2008","unstructured":"Walker MP, Rajendra TK, Saieva L, Fuentes JL, Pellizzoni L, Matera AG. SMN complex localizes to the sarcomeric Z-disc and is a proteolytic target of calpain. Hum Mol Genet. 2008;17:3399\u2013410. https:\/\/doi.org\/10.1093\/hmg\/ddn234.","journal-title":"Hum Mol Genet"},{"key":"3743_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0613-5","volume":"12","author":"CA Wijngaarde","year":"2017","unstructured":"Wijngaarde CA, Blank AC, Stam M, Wadman RI, van den Berg LH, van der Pol WL. Cardiac pathology in spinal muscular atrophy: a systematic review. Orphanet J Rare Dis. 2017;12:67. https:\/\/doi.org\/10.1186\/s13023-017-0613-5.","journal-title":"Orphanet J Rare Dis"},{"key":"3743_CR97","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.yjmcc.2012.01.005","volume":"52","author":"M Shababi","year":"2012","unstructured":"Shababi M, Habibi J, Ma L, Glascock JJ, Sowers JR, Lorson CL. Partial restoration of cardio-vascular defects in a rescued severe model of spinal muscular atrophy. J Mol Cell Cardiol. 2012;52:1074\u201382. https:\/\/doi.org\/10.1016\/j.yjmcc.2012.01.005.","journal-title":"J Mol Cell Cardiol"},{"key":"3743_CR98","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.70303","author":"S Vrettou","year":"2026","unstructured":"Vrettou S, Wirth B. Organ-specific redox imbalances in spinal muscular atrophy mice are partially rescued by SMN antisense oligonucleotides. FEBS Lett. 2026. https:\/\/doi.org\/10.1002\/1873-3468.70303.","journal-title":"FEBS Lett"},{"key":"3743_CR99","doi-asserted-by":"publisher","DOI":"10.1172\/JCI153430","volume":"132","author":"H Zhou","year":"2022","unstructured":"Zhou H, Hong Y, Scoto M, et al. Microvasculopathy in spinal muscular atrophy is driven by a reversible autonomous endothelial cell defect. J Clin Invest. 2022;132:e153430. https:\/\/doi.org\/10.1172\/JCI153430.","journal-title":"J Clin Invest"},{"key":"3743_CR100","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jpeds.2009.01.071","volume":"155","author":"APQC Araujo","year":"2009","unstructured":"Araujo APQC, Araujo M, Swoboda KJ. Vascular perfusion abnormalities in infants with spinal muscular atrophy. J Pediatr. 2009;155:292\u20134. https:\/\/doi.org\/10.1016\/j.jpeds.2009.01.071.","journal-title":"J Pediatr"},{"key":"3743_CR101","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/ana.24549","volume":"79","author":"E Somers","year":"2016","unstructured":"Somers E, Lees RD, Hoban K, et al. Vascular defects and spinal cord hypoxia in spinal muscular atrophy. Ann Neurol. 2016;79:217\u201330. https:\/\/doi.org\/10.1002\/ana.24549.","journal-title":"Ann Neurol"},{"key":"3743_CR102","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155032","volume":"11","author":"P Sintusek","year":"2016","unstructured":"Sintusek P, Catapano F, Angkathunkayul N, et al. Histopathological defects in intestine in severe spinal muscular atrophy mice are improved by systemic antisense oligonucleotide treatment. PLoS ONE. 2016;11:e0155032. https:\/\/doi.org\/10.1371\/journal.pone.0155032.","journal-title":"PLoS ONE"},{"key":"3743_CR103","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1093\/hmg\/ddaa126","volume":"29","author":"H Allardyce","year":"2020","unstructured":"Allardyce H, Kuhn D, Hernandez-Gerez E, et al. Renal pathology in a mouse model of severe spinal muscular atrophy is associated with downregulation of glial cell-line derived neurotrophic factor (GDNF). Hum Mol Genet. 2020;29:2365\u201378. https:\/\/doi.org\/10.1093\/hmg\/ddaa126.","journal-title":"Hum Mol Genet"},{"key":"3743_CR104","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.neulet.2013.03.052","volume":"544","author":"E Somers","year":"2013","unstructured":"Somers E, Riessland M, Schreml J, Wirth B, Gillingwater TH, Parson SH. Increasing SMN levels using the histone deacetylase inhibitor SAHA ameliorates defects in skeletal muscle microvasculature in a mouse model of severe spinal muscular atrophy. Neurosci Lett. 2013;544:100\u20134. https:\/\/doi.org\/10.1016\/j.neulet.2013.03.052.","journal-title":"Neurosci Lett"},{"key":"3743_CR105","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40478-026-02232-y","volume":"14","author":"H Allardyce","year":"2026","unstructured":"Allardyce H, Lanz H, Lawrence BD, Crawford TO, Sumner CJ, Parson SH. Microvascular pathology in the spinal cord of severe spinal muscular atrophy patients. Acta Neuropathol Commun. 2026;14:65. https:\/\/doi.org\/10.1186\/s40478-026-02232-y.","journal-title":"Acta Neuropathol Commun"},{"key":"3743_CR106","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.arcped.2024.03.010","volume":"31","author":"F Bensoussan","year":"2024","unstructured":"Bensoussan F, Costa G, Blanchard A, et al. Paradoxical metabolic acidosis after vomiting in children with spinal muscular atrophy: a report of 9 patients. Arch Pediatr. 2024;31:451\u20134. https:\/\/doi.org\/10.1016\/j.arcped.2024.03.010.","journal-title":"Arch Pediatr"},{"key":"3743_CR107","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.aed.2025.02.001","volume":"12","author":"M Aguilera-Astudillo","year":"2025","unstructured":"Aguilera-Astudillo M, Zahir D, Ullah MS, Mubeen F, Saand A, Shakil J. Nondiabetic ketoacidosis in a patient with spinal muscular atrophy type\u00a0II. AACE Endocrinol Diabetes. 2025;12:8\u201310. https:\/\/doi.org\/10.1016\/j.aed.2025.02.001.","journal-title":"AACE Endocrinol Diabetes"},{"key":"3743_CR108","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.nmd.2011.09.007","volume":"22","author":"M Bowerman","year":"2012","unstructured":"Bowerman M, Murray LM, Beauvais A, Pinheiro B, Kothary R. A critical smn threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology. Neuromuscul Disord. 2012;22:263\u201376. https:\/\/doi.org\/10.1016\/j.nmd.2011.09.007.","journal-title":"Neuromuscul Disord"},{"key":"3743_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015887","volume":"5","author":"SM Hammond","year":"2010","unstructured":"Hammond SM, Gogliotti RG, Rao V, Beauvais A, Kothary R, DiDonato CJ. Mouse survival motor neuron alleles that mimic SMN2 splicing and are inducible rescue embryonic lethality early in development but not late. PLoS ONE. 2010;5:e15887. https:\/\/doi.org\/10.1371\/journal.pone.0015887.","journal-title":"PLoS ONE"},{"key":"3743_CR110","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/hmg\/ddm367","volume":"17","author":"LM Murray","year":"2008","unstructured":"Murray LM, Comley LH, Thomson D, Parkinson N, Talbot K, Gillingwater TH. Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Hum Mol Genet. 2008;17:949\u201362. https:\/\/doi.org\/10.1093\/hmg\/ddm367.","journal-title":"Hum Mol Genet"},{"key":"3743_CR111","doi-asserted-by":"publisher","first-page":"11559","DOI":"10.1523\/JNEUROSCI.1528-17.2017","volume":"37","author":"T le Hao","year":"2017","unstructured":"le Hao T, Duy PQ, An M, et al. HuD and the survival motor neuron protein interact in motoneurons and are essential for motoneuron development, function, and mRNA regulation. J Neurosci. 2017;37:11559\u201371. https:\/\/doi.org\/10.1523\/JNEUROSCI.1528-17.2017.","journal-title":"J Neurosci"},{"key":"3743_CR112","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adv4656","volume":"17","author":"B Borges","year":"2025","unstructured":"Borges B, Brown SM, Chen W-J, et al. Intra-amniotic antisense oligonucleotide treatment improves phenotypes in preclinical models of spinal muscular atrophy. Sci Transl Med. 2025;17:eadv4656. https:\/\/doi.org\/10.1126\/scitranslmed.adv4656.","journal-title":"Sci Transl Med"},{"key":"3743_CR113","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/hmg\/ddad202","volume":"33","author":"A Reilly","year":"2024","unstructured":"Reilly A, Yaworski R, Beauvais A, Schneider BL, Kothary R. Long term peripheral AAV9-SMN gene therapy promotes survival in a mouse model of spinal muscular atrophy. Hum Mol Genet. 2024;33:510\u20139. https:\/\/doi.org\/10.1093\/hmg\/ddad202.","journal-title":"Hum Mol Genet"},{"key":"3743_CR114","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1083\/jcb.200210117","volume":"161","author":"S Nicole","year":"2003","unstructured":"Nicole S, Desforges B, Millet G, et al. Intact satellite cells lead to remarkable protection against Smn gene defect in differentiated skeletal muscle. J Cell Biol. 2003;161:571\u201382. https:\/\/doi.org\/10.1083\/jcb.200210117.","journal-title":"J Cell Biol"},{"key":"3743_CR115","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fmolb.2016.00007","volume":"3","author":"MER Butchbach","year":"2016","unstructured":"Butchbach MER. Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases. Front Mol Biosci. 2016;3:7. https:\/\/doi.org\/10.3389\/fmolb.2016.00007.","journal-title":"Front Mol Biosci"},{"key":"3743_CR116","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22157896","volume":"22","author":"MER Butchbach","year":"2021","unstructured":"Butchbach MER. Genomic variability in the survival motor neuron genes (SMN1 and SMN2): implications for spinal muscular atrophy phenotype and therapeutics development. Int J Mol Sci. 2021;22:7896. https:\/\/doi.org\/10.3390\/ijms22157896.","journal-title":"Int J Mol Sci"},{"key":"3743_CR117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017067","volume":"6","author":"Y-N Su","year":"2011","unstructured":"Su Y-N, Hung C-C, Lin S-Y, et al. Carrier screening for spinal muscular atrophy (SMA) in 107,611 pregnant women during the period\u00a02005-2009: a prospective population-based cohort study. PLoS ONE. 2011;6:e17067. https:\/\/doi.org\/10.1371\/journal.pone.0017067.","journal-title":"PLoS ONE"},{"key":"3743_CR118","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/GIM.0b013e318188d069","volume":"10","author":"TW Prior","year":"2008","unstructured":"Prior TW, Professional Practice and Guidelines Committee. Carrier screening for spinal muscular atrophy. Genet Med. 2008;10:840\u20132. https:\/\/doi.org\/10.1097\/GIM.0b013e318188d069.","journal-title":"Genet Med"},{"key":"3743_CR119","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1525-1578(10)60680-0","volume":"4","author":"S Ogino","year":"2002","unstructured":"Ogino S, Leonard DGB, Rennert H, Wilson RB. Spinal muscular atrophy genetic testing experience at an academic medical center. J Mol Diagn. 2002;4:53\u20138. https:\/\/doi.org\/10.1016\/S1525-1578(10)60680-0.","journal-title":"J Mol Diagn"},{"key":"3743_CR120","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/sj.ejhg.5200210","volume":"6","author":"JE Taylor","year":"1998","unstructured":"Taylor JE, Thomas NH, Lewis CM, et al. Correlation of SMNt and SMNc gene copy number with age of onset and survival in spinal muscular atrophy. Eur J Hum Genet. 1998;6:467\u201374. https:\/\/doi.org\/10.1038\/sj.ejhg.5200210.","journal-title":"Eur J Hum Genet"},{"key":"3743_CR121","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/ana.26788","volume":"94","author":"M Ricci","year":"2023","unstructured":"Ricci M, Cicala G, Capasso A, et al. Clinical phenotype of pediatric and adult patients with spinal muscular atrophy with four SMN2 copies: are they really all stable? Ann Neurol. 2023;94:1126\u201335. https:\/\/doi.org\/10.1002\/ana.26788.","journal-title":"Ann Neurol"},{"key":"3743_CR122","doi-asserted-by":"publisher","first-page":"e200222","DOI":"10.1212\/NXG.0000000000200222","volume":"11","author":"L Gerin","year":"2025","unstructured":"Gerin L, Ropars J, Garcia-Uzquiano R, et al. Spectrum of phenotypes in SMA patients with 4 SMN2 copies in the French population: Registre SMA France. Neurol Genet. 2025;11:e200222. https:\/\/doi.org\/10.1212\/NXG.0000000000200222.","journal-title":"Neurol Genet"},{"key":"3743_CR123","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s00439-006-0156-7","volume":"119","author":"B Wirth","year":"2006","unstructured":"Wirth B, Brichta L, Schrank B, et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. 2006;119:422\u20138. https:\/\/doi.org\/10.1007\/s00439-006-0156-7.","journal-title":"Hum Genet"},{"key":"3743_CR124","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase\u00a01 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86:890\u20137. https:\/\/doi.org\/10.1212\/WNL.0000000000002445.","journal-title":"Neurology"},{"key":"3743_CR125","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40263-022-00899-0","volume":"36","author":"D MacCannell","year":"2022","unstructured":"MacCannell D, Berger Z, Kirschner J, et al. Restoration of nusinersen levels following treatment interruption in people with spinal muscular atrophy: simulations based on a population pharmacokinetic model. CNS Drugs. 2022;36:181\u201390. https:\/\/doi.org\/10.1007\/s40263-022-00899-0.","journal-title":"CNS Drugs"},{"key":"3743_CR126","unstructured":"Biogen Inc. SPINRAZA (nusinersen) injection, for intrathecal use: prescribing information. US Food and Drug Administration; 2026 Mar. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/209531s016lbl.pdf. Accessed 13 June 2026."},{"key":"3743_CR127","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/s41591-025-04193-6","volume":"32","author":"RS Finkel","year":"2026","unstructured":"Finkel RS, Crawford TO, Mercuri E, et al. High-dose nusinersen for spinal muscular atrophy: a phase\u00a03 randomized trial. Nat Med. 2026;32:1095\u2013104. https:\/\/doi.org\/10.1038\/s41591-025-04193-6.","journal-title":"Nat Med"},{"key":"3743_CR128","unstructured":"Novartis Gene Therapies, Inc. ZOLGENSMA (onasemnogene abeparvovec-xioi) suspension, for intravenous infusion: prescribing information. US Food and Drug Administration; 2025 Feb. https:\/\/www.fda.gov\/media\/126109\/download. Accessed 13 June 2026."},{"key":"3743_CR129","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-021-01483-7","volume":"27","author":"G Thomsen","year":"2021","unstructured":"Thomsen G, Burghes AHM, Hsieh C, et al. Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue. Nat Med. 2021;27:1701\u201311. https:\/\/doi.org\/10.1038\/s41591-021-01483-7.","journal-title":"Nat Med"},{"key":"3743_CR130","unstructured":"Novartis Gene Therapies, Inc. ITVISMA (onasemnogene abeparvovec-brve) suspension, for intrathecal injection: prescribing information. US Food and Drug Administration; 2025 Nov. https:\/\/www.fda.gov\/media\/189857\/download. Accessed 13 June 2026."},{"key":"3743_CR131","unstructured":"Genentech, Inc. EVRYSDI (risdiplam) for oral solution; EVRYSDI (risdiplam) tablets, for oral use: prescribing information. US Food and Drug Administration; 2026 Feb. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/213535Orig1s017%3B219285Orig1s002correctedlbl.pdf. Accessed 13 June 2026."},{"key":"3743_CR132","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.447","volume":"6","author":"A Poirier","year":"2018","unstructured":"Poirier A, Weetall M, Heinig K, et al. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol Res Perspect. 2018;6:e00447. https:\/\/doi.org\/10.1002\/prp2.447.","journal-title":"Pharmacol Res Perspect"},{"key":"3743_CR133","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","volume":"61","author":"H Ratni","year":"2018","unstructured":"Ratni H, Ebeling M, Baird J, et al. Discovery of Risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018;61:6501\u201317. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b00741.","journal-title":"J Med Chem"},{"key":"3743_CR134","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/acn3.51562","volume":"9","author":"RS Finkel","year":"2022","unstructured":"Finkel RS, Ryan MM, Pascual Pascual SI, et al. Scientific rationale for a higher dose of nusinersen. Ann Clin Transl Neurol. 2022;9:819\u201329. https:\/\/doi.org\/10.1002\/acn3.51562.","journal-title":"Ann Clin Transl Neurol"},{"key":"3743_CR135","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1111\/ene.15499","volume":"30","author":"E Mercuri","year":"2023","unstructured":"Mercuri E, Baranello G, Boespflug-Tanguy O, et al. Risdiplam in types 2 and 3 spinal muscular atrophy: a randomised, placebo-controlled, dose-finding trial followed by 24\u00a0months of treatment. Eur J Neurol. 2023;30:1945\u201356. https:\/\/doi.org\/10.1111\/ene.15499.","journal-title":"Eur J Neurol"},{"key":"3743_CR136","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/bcp.13786","volume":"85","author":"S Sturm","year":"2019","unstructured":"Sturm S, G\u00fcnther A, Jaber B, et al. A phase\u00a01\u00a0healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. Br J Clin Pharmacol. 2019;85:181\u201393. https:\/\/doi.org\/10.1111\/bcp.13786.","journal-title":"Br J Clin Pharmacol"},{"key":"3743_CR137","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00415-005-0912-y","volume":"253","author":"I Cusc\u00f3","year":"2006","unstructured":"Cusc\u00f3 I, Barcel\u00f3 MJ, Rojas-Garc\u00eda R, et al. SMN2 copy number predicts acute or chronic spinal muscular atrophy but does not account for intrafamilial variability in siblings. J Neurol. 2006;253:21\u20135. https:\/\/doi.org\/10.1007\/s00415-005-0912-y.","journal-title":"J Neurol"},{"key":"3743_CR138","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1126\/science.1155085","volume":"320","author":"GE Oprea","year":"2008","unstructured":"Oprea GE, Kr\u00f6ber S, McWhorter ML, et al. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science. 2008;320:524\u20137. https:\/\/doi.org\/10.1126\/science.1155085.","journal-title":"Science"},{"key":"3743_CR139","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1053\/ejpn.1999.0181","volume":"3","author":"V Dubowitz","year":"1999","unstructured":"Dubowitz V. Very severe spinal muscular atrophy (SMA type\u00a00): an expanding clinical phenotype. Eur J Paediatr Neurol. 1999;3:49\u201351. https:\/\/doi.org\/10.1053\/ejpn.1999.0181.","journal-title":"Eur J Paediatr Neurol"},{"key":"3743_CR140","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1053\/ejpn.1999.0184","volume":"3","author":"MJ MacLeod","year":"1999","unstructured":"MacLeod MJ, Taylor JE, Lunt PW, Mathew CG, Robb SA. Prenatal onset spinal muscular atrophy. Eur J Paediatr Neurol. 1999;3:65\u201372. https:\/\/doi.org\/10.1053\/ejpn.1999.0184.","journal-title":"Eur J Paediatr Neurol"},{"key":"3743_CR141","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1523\/JNEUROSCI.3631-10.2011","volume":"31","author":"C Fallini","year":"2011","unstructured":"Fallini C, Zhang H, Su Y, et al. The survival of motor neuron (SMN) protein interacts with the mRNA-binding protein HuD and regulates localization of poly(A) mRNA in primary motor neuron axons. J Neurosci. 2011;31:3914\u201325. https:\/\/doi.org\/10.1523\/JNEUROSCI.3631-10.2011.","journal-title":"J Neurosci"},{"key":"3743_CR142","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ajhg.2017.01.005","volume":"100","author":"M Riessland","year":"2017","unstructured":"Riessland M, Kaczmarek A, Schneider S, et al. Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis. Am J Hum Genet. 2017;100:297\u2013315. https:\/\/doi.org\/10.1016\/j.ajhg.2017.01.005.","journal-title":"Am J Hum Genet"},{"key":"3743_CR143","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ajhg.2009.08.002","volume":"85","author":"TW Prior","year":"2009","unstructured":"Prior TW, Krainer AR, Hua Y, et al. A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet. 2009;85:408\u201313. https:\/\/doi.org\/10.1016\/j.ajhg.2009.08.002.","journal-title":"Am J Hum Genet"},{"key":"3743_CR144","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00439-019-01983-0","volume":"138","author":"C Ruhno","year":"2019","unstructured":"Ruhno C, McGovern VL, Avenarius MR, et al. Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype. Hum Genet. 2019;138:241\u201356. https:\/\/doi.org\/10.1007\/s00439-019-01983-0.","journal-title":"Hum Genet"},{"key":"3743_CR145","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/hmg\/ddn357","volume":"18","author":"J Hauke","year":"2009","unstructured":"Hauke J, Riessland M, Lunke S, et al. Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Hum Mol Genet. 2009;18:304\u201317. https:\/\/doi.org\/10.1093\/hmg\/ddn357.","journal-title":"Hum Mol Genet"},{"key":"3743_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-023-00256-2","volume":"3","author":"T Nuzzo","year":"2023","unstructured":"Nuzzo T, Russo R, Errico F, et al. Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients. Commun Med. 2023;3:28. https:\/\/doi.org\/10.1038\/s43856-023-00256-2.","journal-title":"Commun Med"},{"key":"3743_CR147","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3233\/JND-230011","volume":"10","author":"J Sun","year":"2023","unstructured":"Sun J, Harrington MA, Porter B, TREAT-NMD Global Registry Network for SMA. Sex difference in spinal muscular atrophy patients - are males more vulnerable? J Neuromuscul Dis. 2023;10:847\u201367. https:\/\/doi.org\/10.3233\/JND-230011.","journal-title":"J Neuromuscul Dis"},{"key":"3743_CR148","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","volume":"52","author":"K Zerres","year":"1995","unstructured":"Zerres K, Rudnik-Sch\u00f6neborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52:518\u201323. https:\/\/doi.org\/10.1001\/archneur.1995.00540290108025.","journal-title":"Arch Neurol"},{"key":"3743_CR149","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0022-510x(96)00284-5","volume":"146","author":"K Zerres","year":"1997","unstructured":"Zerres K, Rudnik-Sch\u00f6neborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type\u00a0II and III SMA): 569 patients. J Neurol Sci. 1997;146:67\u201372. https:\/\/doi.org\/10.1016\/s0022-510x(96)00284-5.","journal-title":"J Neurol Sci"},{"key":"3743_CR150","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/hmg\/ddae190","volume":"34","author":"JC Lee","year":"2025","unstructured":"Lee JC, Chung WK, Pisapia DJ, Henderson CE. Motor pool selectivity of neuromuscular degeneration in type\u00a0I spinal muscular atrophy is conserved between human and mouse. Hum Mol Genet. 2025;34:347\u201367. https:\/\/doi.org\/10.1093\/hmg\/ddae190.","journal-title":"Hum Mol Genet"},{"key":"3743_CR151","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s12031-007-0024-5","volume":"32","author":"M Bowerman","year":"2007","unstructured":"Bowerman M, Shafey D, Kothary R. Smn depletion alters profilin II expression and leads to upregulation of the RhoA\/ROCK pathway and defects in neuronal integrity. J Mol Neurosci. 2007;32:120\u201331. https:\/\/doi.org\/10.1007\/s12031-007-0024-5.","journal-title":"J Mol Neurosci"},{"key":"3743_CR152","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1523\/JNEUROSCI.5775-11.2012","volume":"32","author":"RG Gogliotti","year":"2012","unstructured":"Gogliotti RG, Quinlan KA, Barlow CB, Heier CR, Heckman CJ, Didonato CJ. Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor defects are a consequence, not a cause, of motor neuron dysfunction. J Neurosci. 2012;32:3818\u201329. https:\/\/doi.org\/10.1523\/JNEUROSCI.5775-11.2012.","journal-title":"J Neurosci"},{"key":"3743_CR153","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1007\/s00415-023-11787-y","volume":"270","author":"HS Lapp","year":"2023","unstructured":"Lapp HS, Freigang M, Hagenacker T, Weiler M, Wurster CD, G\u00fcnther R. Biomarkers in 5q-associated spinal muscular atrophy-a narrative review. J Neurol. 2023;270:4157\u201378. https:\/\/doi.org\/10.1007\/s00415-023-11787-y.","journal-title":"J Neurol"},{"key":"3743_CR154","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3233\/JND-230054","volume":"10","author":"J Glascock","year":"2023","unstructured":"Glascock J, Darras BT, Crawford TO, et al. Identifying biomarkers of spinal muscular atrophy for further development. J Neuromuscul Dis. 2023;10:937\u201354. https:\/\/doi.org\/10.3233\/JND-230054.","journal-title":"J Neuromuscul Dis"},{"key":"3743_CR155","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/acn3.779","volume":"6","author":"BT Darras","year":"2019","unstructured":"Darras BT, Crawford TO, Finkel RS, et al. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol. 2019;6:932\u201344. https:\/\/doi.org\/10.1002\/acn3.779.","journal-title":"Ann Clin Transl Neurol"},{"key":"3743_CR156","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1515\/cclm-2023-1311","volume":"62","author":"S Bayoumy","year":"2024","unstructured":"Bayoumy S, Verberk IMW, Vermunt L, et al. Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges. Clin Chem Lab Med. 2024;62:1252\u201365. https:\/\/doi.org\/10.1515\/cclm-2023-1311.","journal-title":"Clin Chem Lab Med"},{"key":"3743_CR157","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/mus.21838","volume":"42","author":"A Lewelt","year":"2010","unstructured":"Lewelt A, Krosschell KJ, Scott C, et al. Compound muscle action potential and motor function in children with spinal muscular atrophy. Muscle Nerve. 2010;42:703\u20138. https:\/\/doi.org\/10.1002\/mus.21838.","journal-title":"Muscle Nerve"},{"key":"3743_CR158","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41436-020-00987-w","volume":"23","author":"W-C Weng","year":"2021","unstructured":"Weng W-C, Hsu Y-K, Chang F-M, et al. CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening. Genet Med. 2021;23:415\u201320. https:\/\/doi.org\/10.1038\/s41436-020-00987-w.","journal-title":"Genet Med"},{"key":"3743_CR159","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.clinph.2018.08.025","volume":"129","author":"G Querin","year":"2018","unstructured":"Querin G, Lenglet T, Debs R, et al. The motor unit number index (MUNIX) profile of patients with adult spinal muscular atrophy. Clin Neurophysiol. 2018;129:2333\u201340. https:\/\/doi.org\/10.1016\/j.clinph.2018.08.025.","journal-title":"Clin Neurophysiol"},{"key":"3743_CR160","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.clinph.2018.11.009","volume":"130","author":"R G\u00fcnther","year":"2019","unstructured":"G\u00fcnther R, Neuwirth C, Koch JC, et al. Motor unit number index (MUNIX) of hand muscles is a disease biomarker for adult spinal muscular atrophy. Clin Neurophysiol. 2019;130:315\u20139. https:\/\/doi.org\/10.1016\/j.clinph.2018.11.009.","journal-title":"Clin Neurophysiol"},{"key":"3743_CR161","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28:103\u201315. https:\/\/doi.org\/10.1016\/j.nmd.2017.11.005.","journal-title":"Neuromuscul Disord"},{"key":"3743_CR162","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/mus.25385","volume":"55","author":"H Durmus","year":"2017","unstructured":"Durmus H, Yilmaz R, Gulsen-Parman Y, et al. Muscle magnetic resonance imaging in spinal muscular atrophy type\u00a03: selective and progressive involvement. Muscle Nerve. 2017;55:651\u20136. https:\/\/doi.org\/10.1002\/mus.25385.","journal-title":"Muscle Nerve"},{"key":"3743_CR163","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.4473","volume":"34","author":"LAM Otto","year":"2021","unstructured":"Otto LAM, Froeling M, van Eijk RPA, et al. Quantification of disease progression in spinal muscular atrophy with muscle MRI\u2014a pilot study. NMR Biomed. 2021;34:e4473. https:\/\/doi.org\/10.1002\/nbm.4473.","journal-title":"NMR Biomed"},{"key":"3743_CR164","doi-asserted-by":"publisher","first-page":"e33572","DOI":"10.1371\/journal.pone.0033572","volume":"7","author":"TO Crawford","year":"2012","unstructured":"Crawford TO, Paushkin SV, Kobayashi DT, et al. Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS One. 2012;7:e33572. https:\/\/doi.org\/10.1371\/journal.pone.0033572.","journal-title":"PLoS One"},{"key":"3743_CR165","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28:197\u2013207. https:\/\/doi.org\/10.1016\/j.nmd.2017.11.004.","journal-title":"Neuromuscul Disord"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03743-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03743-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03743-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:33:38Z","timestamp":1786340018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03743-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":165,"alternative-id":["3743"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03743-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kentaro Okamoto has received honoraria for invited lectures from Biogen Japan (2021) and Chugai Pharmaceutical Co., Ltd. (a member of the Roche Group) (2022). Kentaro Okamoto declares no other conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by the author.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}